Australian Clinical Labs Ltd (ACL) AI Stock Analysis

• Market Cap: AU$367.14M
• Dividend Yield: 4.6%
• Average Volume (3M): 867.30K
• Price to Earnings (P/E): 23.9
• Beta (1Y): 0.98
• Revenue Growth: 6.73%
• EPS Growth: 37.16%
• Country: AU
• Employees: 4,900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.07
• Shares Outstanding: 190,308,600
• 10 Day Avg. Volume: 799,589
• 30 Day Avg. Volume: 867,296
• PEG Ratio: 0.39
• Price to Book (P/B): 3.09
• Price to Sales (P/S): 0.71
• P/FCF Ratio: 3.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$2.33
• Price Target Upside: 19.85% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4
• EPS Forecast (FY): 0.17
• Revenue Forecast (FY): AU$736.49M

• Rating: 59 Neutral
• Price Target: AU$2.00 ▲(3.09% Upside)
• Action: Downgraded Date: 02/17/26
• Date: Action: Downgraded 02/17/26

Overall score is held back primarily by weak technicals (price below all major moving averages with negative MACD), partially offset by solid cash flow generation and an attractive valuation (moderate P/E and high dividend yield). Financial leverage remains a key risk despite decent ROE and improving gross margin.

Positive Factors

Cash Generation

ACL's rising free cash flow and high cash conversion ratios indicate durable ability to fund operations, reinvest in labs, pay dividends and service debt. Strong cash conversion reduces reliance on external finance and supports strategic flexibility over the medium term.

Improved Gross Margin

A materially higher gross margin reflects better cost control, pricing or a more favorable test mix. Sustained margin expansion at the gross level supports operating leverage and provides room to absorb cost shocks or invest in higher-complexity testing capabilities.

Stable Fee-for-Service Model

ACL's diversified fee-for-service revenues across community, hospital and specialist testing create stable structural demand. Institutional contracts and centralized specialist labs provide scale advantages and recurring referral streams that support medium-term revenue predictability.

Negative Factors

High Leverage

Significant leverage constrains financial flexibility, raises interest expense sensitivity and limits room for strategic investment or M&A. In a reimbursement-pressured sector, high debt increases risk of margin compression and reduces resilience to operational shocks.

Thin Net Margin

Despite better gross margins, low net profitability indicates limited ability to convert revenue into retained earnings after overhead, financing and tax. This constrains balance sheet repair, reduces capacity to self-fund growth and leaves less buffer for pricing or volume shocks.

Sluggish Revenue Growth

Very slow top-line growth suggests limited organic expansion and competitive pressure on volumes or pricing. Persistently low revenue momentum impedes scaling of fixed-cost leverage and makes margin improvement and return-profile gains harder to sustain without structural market or service expansions.

Australian Clinical Labs Ltd Business Overview & Revenue Model

Company Description

Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. The company was incorporated in 2020 and is headquartered in Clayton, Australia.

How the Company Makes Money

ACL makes money primarily by performing diagnostic pathology tests and charging for those services. Its revenue model is largely fee-for-service: when a clinician requests a pathology test (e.g., blood, urine, tissue/cytology and other laboratory analyses), ACL processes the sample through its laboratories and is paid per test or per episode of testing. Key revenue streams typically include (1) community/referrer-based pathology, where tests are ordered by general practitioners and specialists and processed via ACL’s collection centres; (2) hospital and institutional pathology, where ACL provides testing services to hospitals and other healthcare institutions (including through contracted service arrangements where applicable); and (3) specialized or higher-complexity testing performed in centralized laboratories that can command higher reimbursement or pricing. Payments are generally received from a mix of government reimbursement mechanisms (where applicable), private health insurers, and out-of-pocket patient payments, depending on the test type, setting, and patient coverage. Significant earnings drivers include test volume (number of referrals), test mix (routine versus specialized), contracted service volumes from institutions, and operational scale/efficiency from laboratory and logistics networks. Specific partnerships: null.

Australian Clinical Labs Ltd Financial Statement Overview

Summary

Income statement is mixed (modest 1.79% revenue growth, improved gross margin to 36.54%, but low net margin at 4.37%). Balance sheet adds risk from high leverage (debt-to-equity 1.69, low equity ratio) despite solid ROE (18.93%). Cash flow is a relative strength (free cash flow up 8.67%, strong cash conversion with OCF/NI 0.84 and FCF/NI 0.95).

Income Statement

Australian Clinical Labs Ltd has shown a mixed performance in its income statement. The company experienced a slight revenue growth of 1.79% in the most recent year, following a decline in the previous periods. Gross profit margin improved significantly to 36.54%, indicating better cost management. However, the net profit margin remains low at 4.37%, suggesting challenges in translating revenue into profit. The EBIT and EBITDA margins are moderate, reflecting stable operational efficiency.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 1.69, indicating significant leverage, which could pose a risk if not managed properly. Return on equity is relatively strong at 18.93%, showing effective use of equity to generate profits. However, the equity ratio is low, suggesting a higher reliance on debt financing.

Cash Flow

Cash flow analysis shows a positive trend with an 8.67% growth in free cash flow, indicating improved cash generation capabilities. The operating cash flow to net income ratio is strong at 0.84, suggesting good cash conversion from earnings. The free cash flow to net income ratio is high at 0.95, reflecting efficient cash management.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	733.52M	741.27M	689.73M	692.10M	989.30M	641.31M
Gross Profit	209.96M	270.86M	138.45M	566.02M	781.71M	521.73M
EBITDA	133.59M	81.36M	169.65M	184.93M	372.75M	196.67M
Net Income	26.31M	32.43M	23.93M	35.90M	178.24M	60.37M
Balance Sheet
Total Assets	562.50M	574.84M	593.06M	578.91M	628.04M	474.70M
Cash, Cash Equivalents and Short-Term Investments	23.14M	22.12M	26.84M	20.59M	27.51M	36.28M
Total Debt	453.61M	290.38M	308.90M	316.32M	262.38M	294.26M
Total Liabilities	411.46M	402.86M	415.30M	406.24M	395.49M	392.79M
Stockholders Equity	150.57M	171.35M	177.53M	172.42M	232.44M	81.90M
Cash Flow
Free Cash Flow	156.69M	174.39M	153.09M	136.75M	262.83M	144.36M
Operating Cash Flow	164.57M	182.80M	159.59M	143.68M	284.09M	153.86M
Investing Cash Flow	-8.32M	-8.89M	-7.25M	-12.18M	-72.04M	-6.08M
Financing Cash Flow	-154.65M	-178.74M	-146.14M	-137.88M	-220.91M	-147.37M

Australian Clinical Labs Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.94
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACL, the sentiment is Negative. The current price of 1.94 is below the 20-day moving average (MA) of 2.10, below the 50-day MA of 2.34, and below the 200-day MA of 2.54, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 27.84 is Positive, neither overbought nor oversold. The STOCH value of 4.62 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ACL.

Australian Clinical Labs Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SHL	70 Outperform	AU$9.86B	10.64	6.39%	4.69%	9.44%	-0.37%
ACL	59 Neutral	AU$367.14M	23.92	16.35%	4.60%	6.73%	37.16%
IDX	55 Neutral	AU$905.69M	26.42	2.05%	2.65%	33.54%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HLS	46 Neutral	AU$403.00M	-5.40	-67.21%	―	-23.02%	33.11%

Australian Clinical Labs Ltd Corporate Events

Australian Clinical Labs Reports Daily Progress on On‑Market Share Buy‑Back

Australian Clinical Labs has updated the market on its ongoing on‑market share buy‑back of ordinary fully paid shares. The company reported that it had repurchased a cumulative 6,388,208 shares prior to the latest trading day and bought back an additional 101,500 shares on the previous day, as part of a program first notified in October 2025.

The continued daily execution of the buy‑back indicates active capital management aimed at reducing the number of shares on issue, which can enhance earnings per share and signal confidence in the company’s valuation. Regular updates on the buy‑back also provide transparency for investors tracking the impact of these purchases on liquidity and ownership structure over time.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Cancels Shares Following On-Market Buy-Back

Australian Clinical Labs has cancelled 573,748 fully paid ordinary shares following an on-market share buy-back, as disclosed in its latest capital notification to the exchange. The move reduces the company’s issued capital base and may incrementally enhance earnings per share and capital efficiency for remaining shareholders, signaling ongoing active capital management.

The cessation of these securities, effective 20 March 2026, reflects the company’s use of buy-backs as a tool to return value and optimize its balance sheet. While the transaction size is modest relative to typical market capitalizations, it underscores management’s confidence and may influence trading liquidity and shareholder composition over time.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Updates Progress of On-Market Share Buy-Back

Australian Clinical Labs has continued its on-market share buy-back program, repurchasing a total of 6,138,208 ordinary fully paid shares prior to the latest reporting date. The company bought back a further 250,000 shares on the previous trading day, underscoring ongoing capital management efforts aimed at reducing the share count and potentially enhancing shareholder value.

The latest filing is an update to the buy-back first notified in October 2025, with this announcement dated 23 March 2026. Regular daily notifications signal an active execution of the approved buy-back, which may influence trading liquidity and share price dynamics as the program progresses.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Continues On-Market Share Buy-Back Program

Australian Clinical Labs has an on-market share buy-back in place for its ordinary fully paid shares on the ASX, as part of a capital management program first notified in October 2025. The latest daily update shows that the company repurchased 81,675 shares on the previous trading day, taking total buy-backs to 6,056,533 shares, which incrementally reduces shares on issue and can enhance earnings per share for remaining investors.

The company’s regular buy-back disclosures indicate an ongoing commitment to returning capital to shareholders and actively managing its balance sheet. Continued execution of the buy-back may support the share price and signal management’s confidence in the company’s financial position and future prospects, with implications for valuation and ownership concentration over time.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Updates Market on Progress of On-Market Share Buy-Back

Australian Clinical Labs has provided an updated notification to the ASX on its ongoing on-market share buy-back of ordinary fully paid shares. The latest daily report, dated 18 March 2026, confirms that the company repurchased 80,063 shares in the previous trading day, bringing the total number of shares bought back under the program to 5,923,429.

The continued execution of the on-market buy-back signals management’s commitment to capital management and returning value to shareholders. By reducing the number of shares on issue through regular market purchases, Australian Clinical Labs may enhance earnings per share and support its share price, with implications for investor perception of the company’s financial strength and confidence in its long-term outlook.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Updates Market on Ongoing Share Buy‑Back Activity

Australian Clinical Labs has been conducting an on‑market share buy‑back of its ordinary fully paid shares, as part of a previously announced capital management program first notified in October 2025. The company reported that, as of the latest daily update on 17 March 2026, it had repurchased a cumulative 5,809,588 shares, including 113,841 shares bought back on the previous trading day, signalling ongoing efforts to optimise its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Updates Market on Progress of On‑Market Share Buy-Back

Australian Clinical Labs Limited has updated the market on its ongoing on‑market share buy-back program for its ordinary fully paid shares listed under the ASX code ACL. The company reported that a total of 5,690,543 shares had been repurchased before the previous trading day, with an additional 119,045 shares bought back on the prior day as part of the program.

The continued daily execution of the buy-back, first notified in October 2025, signals management’s active capital management and may indicate confidence in the company’s valuation. This activity can support the share price, reduce the number of shares on issue, and potentially enhance earnings per share, with implications for existing shareholders and the company’s market positioning.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Cancels Over 1 Million Shares in On‑Market Buy‑Back

Australian Clinical Labs has cancelled 1,012,269 ordinary fully paid shares following an on‑market buy‑back completed on 9 March 2026. The reduction in issued capital through the buy‑back may enhance earnings per share and signals ongoing capital management, which can influence investor perception of the company’s financial discipline and shareholder‑return strategy.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Updates Market on Ongoing Share Buy-Back

Australian Clinical Labs Ltd has provided an updated notification to the ASX regarding its ongoing on-market share buy-back of ordinary fully paid shares. The company reported that, as of 11 March 2026, it has repurchased a cumulative 5,607,148 shares, including 83,395 shares bought back on the previous trading day.

The update, which follows the initial buy-back notification lodged on 23 October 2025, confirms the continued execution of the capital management program. This sustained on-market repurchase reduces the company’s free float and may enhance earnings per share, signalling management’s confidence in the business and potentially supporting shareholder value.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Updates Market on Ongoing Share Buy-Back

Australian Clinical Labs Limited has provided an update on its on-market share buy-back program for its ordinary fully paid shares traded under the ASX code ACL. The company reported that, as of the latest notification dated 10 March 2026, it had repurchased a cumulative total of 5,482,785 shares prior to the previous day, with an additional 124,363 shares bought back on the previous trading day.

The ongoing buy-back, which was initially notified in October 2025, indicates a continued effort by the company to manage its capital structure and potentially enhance shareholder value. Regular daily updates signal transparency to investors and may reflect management’s view that the current share price undervalues the company’s prospects, although no explicit rationale was detailed in the announcement.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Reports Ongoing On‑Market Share Buy‑Back Activity

Australian Clinical Labs Ltd, a pathology and diagnostic services provider listed on the ASX, is continuing to execute its on-market share buy-back program for its ordinary fully paid shares. The company operates in the Australian healthcare sector, offering medical laboratory testing and related clinical diagnostics to healthcare providers and patients.

The latest daily update shows that ACL has repurchased a total of 5,408,991 shares prior to the most recent trading day and bought back an additional 73,794 shares on the previous day. The ongoing on-market buy-back signals continued capital management activity, which may support the company’s share price and adjust its capital structure, with potential implications for existing shareholders’ ownership percentages.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Service Rights Lapse Reduces Potential Equity Pool

Australian Clinical Labs has reported a change in its issued capital following the lapse of 125,145 service rights, identified under the ASX security code ACLAD. These rights ceased on 9 January 2026 after the conditions attached to them were not met or became incapable of being satisfied, resulting in a reduction of potential equity-based remuneration instruments on issue.

The cessation of these conditional service rights slightly trims the company’s pool of outstanding performance-linked securities, which can affect future dilution for existing shareholders. It also reflects that specific performance or service conditions set for these awards were not achieved, providing an implicit signal about the outcomes linked to that particular incentive structure.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Updates Market on Progress of On-Market Share Buy-Back

Australian Clinical Labs Ltd has provided an updated notification to the ASX regarding its ongoing on-market share buy-back program for its ordinary fully paid shares. The company reported that a total of 5,113,904 securities had been repurchased prior to the latest trading day, with an additional 150,000 shares bought back on the previous day as part of the daily buy-back reporting.

This continued execution of the buy-back signals ongoing capital management efforts that may support earnings per share and potentially shareholder value by reducing shares on issue. The regular daily notifications also underline the company’s compliance with ASX disclosure requirements and give investors transparency on the pace and scale of the buy-back activity.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Updates Daily On-Market Share Buy-Back Activity

Australian Clinical Labs has disclosed an update to its on-market share buy-back program for its ordinary fully paid shares listed on the ASX under ticker ACL. The filing notes that, as of the latest reporting date, the company continues to execute daily buy-backs as part of a capital management initiative first notified in October 2025.

The update confirms that a total of 5,030,768 shares had been bought back prior to the previous trading day, with an additional 83,136 shares repurchased on that day. The ongoing daily purchases signal the company’s active use of share buy-backs to manage its capital structure, which may support earnings per share and indicate confidence in its valuation for existing shareholders.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Updates Progress on On‑Market Share Buy‑Back

Australian Clinical Labs has provided an updated notification on its on‑market share buy‑back program for its fully paid ordinary shares. The announcement records that, as of the latest daily update, the company has bought back 100,000 securities on the previous day, bringing the cumulative total repurchased to 4,930,768 shares since the buy‑back was first notified in October 2025.

The ongoing on‑market buy‑back signals active capital management by Australian Clinical Labs and may support its share price by reducing the number of shares on issue. Regular daily reporting of repurchases provides transparency for investors and indicates the company’s continued commitment to executing the program over time.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Cancels 900,000 Shares in On‑Market Buy‑Back

Australian Clinical Labs Limited has cancelled 900,000 fully paid ordinary shares as part of an on‑market buy‑back, effective 24 February 2026. The reduction in issued capital signals an active capital management program that may enhance earnings per share and could be interpreted by investors as a sign of confidence in the company’s financial position.

This move slightly tightens the company’s free float and may marginally improve capital efficiency, depending on the buy‑back price relative to intrinsic value. For existing shareholders, the buy‑back‑driven cancellation can be value accretive over time, although it also reduces overall market liquidity in ACL shares.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Reports Daily Progress of On-Market Share Buy-Back

Australian Clinical Labs has provided an updated notification on its on-market share buy-back program for its fully paid ordinary shares. The company reported that, as of the latest daily update, it had repurchased a cumulative total of 4,829,786 shares prior to the previous trading day and bought back an additional 100,982 shares on the previous day.

The announcement, dated 27 February 2026, forms part of an ongoing buy-back that began in October 2025 and is being reported to the ASX through daily amendments. This continued execution of the buy-back signals ongoing capital management activity, potentially supporting earnings per share and indicating confidence in the company’s valuation for existing shareholders.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Citi Group Entities Exit Substantial Holder Position in Australian Clinical Labs

Citigroup Global Markets Australia Pty Limited and related Citi group entities have ceased to be substantial holders in Australian Clinical Labs, after reducing their relevant interest in the company’s ordinary fully paid shares. The change stems from decreased holdings under securities lending arrangements managed through Citibank, N.A. Sydney Branch and Citigroup Global Markets Limited, signaling a notable shift in a key institutional holder’s position in ACL’s share register and potentially altering the company’s institutional ownership profile.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Updates Progress of On‑Market Share Buy‑Back

Australian Clinical Labs Limited has provided an update on its on‑market share buy‑back program for its ordinary fully paid shares. The company reported that a total of 4,670,516 shares had been repurchased before the previous trading day, with an additional 159,270 shares bought back on the prior day as part of the ongoing program.

The latest notification, dated 25 February 2026, confirms that the buy‑back, which was initially announced in October 2025, is continuing as planned. The steady execution of the on‑market buy‑back signals ongoing capital management efforts that may support earnings per share and could be viewed as a sign of confidence in the company’s valuation by management and the board.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Continues On‑Market Share Buy‑Back Program

Australian Clinical Labs has continued its on‑market share buy‑back program, repurchasing a total of 4,470,516 ordinary fully paid shares prior to the latest trading day under the existing mandate first notified in October 2025. The company disclosed that it bought back a further 200,000 shares on the previous day, signalling an ongoing capital management strategy that may support earnings per share and share price stability for investors.

The latest filing, dated 24 February 2026, is an update to an earlier buy‑back notification lodged on 23 February 2026, confirming the continued execution of the program rather than any change in its terms. This steady pace of buy‑backs suggests management’s confidence in the company’s valuation and provides incremental returns to shareholders through a reduced share count in the market.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Updates Market on Ongoing Share Buy-Back

Australian Clinical Labs has continued its on-market share buy-back program, updating the market with a daily notification to the ASX. The company reported that it has repurchased a total of 4,270,516 ordinary fully paid shares prior to the latest trading day.

On the previous day alone, the company bought back an additional 200,000 shares under the existing buy-back mandate first notified in October 2025. The ongoing buy-back reduces the number of shares on issue and may support earnings per share and capital management objectives for existing shareholders.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Director Sarah Butler Acquires Indirect Shareholding

Australian Clinical Labs has disclosed a change in director Sarah Butler’s relevant interests, with Butler acquiring an indirect stake in the company through a trust structure. The transaction signals increased alignment between the director’s interests and shareholders, though the scale of the purchase suggests a modest financial impact on the company’s overall capital structure.

According to the notice, Butler, via Beausoleil Investments Pty Ltd as trustee for the Muskoka Trust, acquired 22,617 ordinary shares in an on-market trade at an average price of $2.21 per share. The acquisition brings her indirect holding in Australian Clinical Labs to 22,617 shares and reflects routine director share trading rather than any change to the company’s strategic direction or operations.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Lifts Total On‑Market Buy‑Back to Over 4 Million Shares

Australian Clinical Labs has continued its on‑market share buy‑back program, repurchasing a further 200,000 ordinary fully paid shares on 19 February 2026. This lifts the total number of shares bought back under the program to 4,070,516, signalling ongoing capital management activity that may support earnings per share and reflects management’s view on the company’s valuation and balance sheet efficiency.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Sets Investor Webinar for 1H26 Results

Australian Clinical Labs will release its financial and operating results for the half year ended 31 December 2025 on 16 February 2026 and will brief investors via a Zoom webinar hosted by CEO Melinda McGrath and CFO Matt Cordingley. The company will provide a recording of the session on its investor website and has outlined how it will collect and handle participants’ personal information for the event in line with its privacy policy, underscoring its ongoing engagement with shareholders and the broader investment community.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Retirement Trust Ceases to Be Substantial Holder in Australian Clinical Labs

Australian Retirement Trust Pty Ltd has notified Australian Clinical Labs Limited that it has ceased to be a substantial shareholder in the company as of 21 January 2026, according to a change in relevant interests disclosed under the Corporations Act. The move indicates a reduction in Australian Retirement Trust’s voting power below the substantial holding threshold, signalling a shift in the company’s institutional investor base that may alter its shareholder dynamics but does not, on its own, imply any change to underlying operations.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Ethical Exits Substantial Holder Position in Australian Clinical Labs

Australian Ethical Investment Limited has notified the market that it has ceased to be a substantial shareholder in Australian Clinical Labs Limited, as formalised in a Form 605 lodged with the ASX. The change reduces Australian Ethical’s significant ownership influence in the pathology provider, signalling a shift in its investment position and potentially altering the shareholder landscape for Australian Clinical Labs, although no further operational or strategic implications were disclosed.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

Australian Clinical Labs Cancels 200,000 Shares Under On‑Market Buy-Back

Australian Clinical Labs Limited has cancelled 200,000 fully paid ordinary shares as part of an on‑market share buy-back, effective 22 December 2025. The reduction in issued capital reflects the company’s ongoing capital management strategy, which may incrementally enhance earnings per share and signal management’s confidence in the business to investors.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.